Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype
Compose a Response to This Article
Other responses
No responses have been published for this article.
